Evidence mapPaperPMID 32089647Full record

ArticleMediators of inflammation2020

Aloe Emodin Reduces Cardiac Inflammation Induced by a High-Fat Diet through the TLR4 Signaling Pathway.

Yingfu Chen, Burong Feng, Ye Yuan, Juan Hu, Wei Zhao, Huiwei Jiang, Wen Li, Ziyi Fan, Zhimin Du

Open access · goldAbstract read
In one paragraph

Article in Mediators of inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Foods (Basel, Switzerland) · 2024
    Review
  6. Article
  7. Formulation, characterization and and evaluation of aloe-emodin-loaded solid dispersions for dissolution enhancement.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024
    Article
  8. Article
  9. Article
  10. Review
  11. FermentedJournal of microbiology and biotechnology · 2023
    Article
  12. Multiple Beneficial Effects of Aloesone fromMolecules (Basel, Switzerland) · 2023
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Yingfu Chen *Institute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.
Burong Feng *Institute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.
Ye YuanInstitute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.ORCID https://orcid.org/0000-0001-5722-1291
Juan HuInstitute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.ORCID https://orcid.org/0000-0003-2028-4883
Wei ZhaoInstitute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.
Huiwei JiangInstitute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.
Wen LiInstitute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.
Ziyi FanInstitute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.
Zhimin DuInstitute of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University (The University Key Laboratory of Drug Research, Heilongjiang Province, Harbin 150086, China.ORCID https://orcid.org/0000-0002-0346-2863
Harbin Medical University · CNMacau University of Science and Technology · MO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAloe emodin (AE) is a lipid-lowering agent, which could be used to treat hyperlipidemia, thereby reducing the risk of cardiovascular disease. Recent evidence suggests that hyperlipidemia is associated with many cardiac pathological alterations and might worsen myocardial damages. PURPOSE: The purpose of this study is to evaluate the potential roles and mechanisms of AE in hyperlipidemia-induced oxidative stress and inflammation in the heart.

methodsWe used a mouse model of hyperlipidemia caused by a high-fat diet (HFD) for 10 weeks and cell culture experimental models of inflammation in the heart stimulated by PA for 14 h. Inflammatory markers were detected by qRT-PCR, WB, and immunofluorescence.

resultsWe demonstrated that the expression levels of proinflammatory cytokines IL-1

conclusionTaken together, our findings disclose that AE could alleviate HFD/PA-induced cardiac inflammation via inhibition of the TLR4/NF-

Indexed as

AnimalsAnthraquinonesDiet, High-FatInflammationIntercellular Adhesion Molecule-1Interleukin-1betaInterleukin-6MaleMiceMyocardiumRats, WistarSignal TransductionToll-Like Receptor 4Tumor Necrosis Factor-alphaVascular Cell Adhesion Molecule-1aloe emodinAnthraquinonesIntercellular Adhesion Molecule-1Interleukin-1betaInterleukin-6Toll-Like Receptor 4Tumor Necrosis Factor-alphaVascular Cell Adhesion Molecule-1

Identifiers

PMID32089647
PMCPMC7025072
OpenAlexW3005405638

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.